Use of exendin-4 to treat impaired glucose tolerance
CA 2334872 C · Owner: Coolidge, Thomas R. · Inventors: Goke, Burkhard; Byrne, Maria; Coolidge, Thomas R.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A composition for the treatment of impaired glucose tolerance (IGT) including a compound which binds to a receptor for glucagon-like peptide-1 and a , pharmaceutical carrier. The amount of the compound present is an effective amount to improve pancreatic .beta.-cell sensitivity to blood glucose levels in a human with IGT. Also, a method for improving the pattern of insulin secretory responses in a human with IGT by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 7, 1999 and granted August 19, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 7, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 7, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.